Annual report cites funding constraints and six subsidiary transaction approvals
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech filed the FY2025-26 annual report for the year ended March 31, 2026. Its annual general meeting is on November 30 via video conference. Management cites two years of funding constraints and an October 2026 rights issue to strengthen capital. Shareholders will vote on transactions with six subsidiaries, each capped at Rs 25 crore for FY2026-27. No consolidated quarterly comparison figures are provided.
The rights issue may strengthen cash but dilute existing holders. Six related-party approvals raise transaction exposure and need monitoring.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.